Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
NCT02780700 · Boehringer Ingelheim · PHASE2 · terminated · last registry update 2025-02-03 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Substance discontinued” | Open Targets' class: study design | Registry record, Boehringer Ingelheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDGFRB in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05064059)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
- 2025-07-18Results posted on the registry: Institut du Cancer de Montpellier - Val d'Aurelle, Regorafenib + Irinotecan (NCT03829462)
- 2025-01-15Results posted on the registry: Institut du Cancer de Montpellier - Val d'Aurelle, Folfirinox + regorafenib (NCT03828799)
- 2024-04-09Results posted on the registry: Merck Sharp & Dohme LLC, pembrolizumab + lenvatinib (NCT04776148)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision